APRE (Aprea Therapeutics) Insider Ownership: 11.13 % (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

APRE Aprea Therapeutics Inc APRE
30 GF Score
Price $0.60
! 1 Warning Sign
View Full Analysis

What is Aprea Therapeutics Insider Ownership?

Aprea Therapeutics APRE -0.71% 30 Insider Ownership is 11.13 % as of Aug. 04, 2026. GuruFocus rates APRE with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aprea Therapeutics's insider ownership is 11.13%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aprea Therapeutics's Institutional Ownership is 18.12%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aprea Therapeutics's Float Percentage Of Total Shares Outstanding is 94.12%.

Aprea Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Aprea Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprea Therapeutics Insider Ownership Chart

Aprea Therapeutics Historical Data

The historical data trend for Aprea Therapeutics can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 22.82 21.67 21.67 21.67 20.00 18.42 11.55 10.92 11.13 11.13
APRE
30GF Score
Aprea Therapeutics Inc APRE
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aprea Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 11.13 % mean?
Aprea Therapeutics (APRE) has a Insider Ownership of 11.13 % as of Aug. 04, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Aprea Therapeutics and its competitors.
Is Aprea Therapeutics' Insider Ownership too high?
Aprea Therapeutics' current Insider Ownership is 11.13 %. Overall, Aprea Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aprea Therapeutics' Insider Ownership compare to SYBX and MTVA?
Aprea Therapeutics' Insider Ownership of 11.13 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Aprea Therapeutics and its competitors. Aprea Therapeutics's current Insider Ownership is 11.13 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprea Therapeutics stock overvalued right now?
Aprea Therapeutics (APRE) has a current Insider Ownership of 11.13 %. The current Insider Ownership is 11.13 %. Aprea Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Aprea Therapeutics (APRE), the current Insider Ownership is 11.13 % as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprea Therapeutics Business Description

Address 3805 Old Easton Road, Doylestown, PA, USA, 18902
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
30GF Score

Get the complete analysis for APRE

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.60
Price